Tesaro Inc. (NASDAQ:TSRO) – Investment analysts at Leerink Swann upped their FY2020 EPS estimates for Tesaro in a research report issued to clients and investors on Sunday. Leerink Swann analyst S. Fernandez now forecasts that the brokerage will earn $9.47 per share for the year, up from their previous forecast of $8.88. Leerink Swann currently has a “Outperform” rating and a $115.00 price objective on the stock.
Tesaro (NASDAQ:TSRO) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.28) earnings per share for the quarter, topping the consensus estimate of ($1.71) by $0.43. The firm had revenue of $36.60 million for the quarter, compared to analysts’ expectations of $4.98 million. Tesaro had a negative return on equity of 205.63% and a negative net margin of 783.97%. During the same quarter last year, the business earned ($1.51) EPS.
Several other research analysts have also recently weighed in on TSRO. Zacks Investment Research cut Tesaro from a “hold” rating to a “sell” rating in a research report on Wednesday, June 15th. FBR & Co boosted their price objective on Tesaro from $65.00 to $93.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 29th. Jefferies Group cut Tesaro from a “buy” rating to a “hold” rating and boosted their price objective for the stock from $53.00 to $75.00 in a research report on Thursday, June 30th. They noted that the move was a valuation call. Mizuho reissued an “outperform” rating and issued a $67.00 price objective on shares of Tesaro in a research report on Thursday, June 30th. Finally, Wells Fargo & Co. reissued an “outperform” rating on shares of Tesaro in a research report on Thursday, June 30th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and thirteen have issued a buy rating to the company. Tesaro presently has an average rating of “Buy” and a consensus target price of $110.11.
Tesaro (NASDAQ:TSRO) traded down 0.49% on Tuesday, reaching $114.77. The company’s stock had a trading volume of 1,159,702 shares. Tesaro has a 12 month low of $29.51 and a 12 month high of $122.89. The firm’s market cap is $5.90 billion. The firm has a 50 day moving average of $97.53 and a 200 day moving average of $70.11.
In related news, VP Jeffrey H. Hanke sold 29,166 shares of the business’s stock in a transaction dated Tuesday, August 30th. The stock was sold at an average price of $86.04, for a total transaction of $2,509,442.64. Following the completion of the transaction, the vice president now directly owns 29,166 shares in the company, valued at $2,509,442.64. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Martin H. Jr. Huber sold 408 shares of the business’s stock in a transaction dated Thursday, September 22nd. The stock was sold at an average price of $108.12, for a total value of $44,112.96. Following the transaction, the senior vice president now owns 1,250 shares of the company’s stock, valued at $135,150. The disclosure for this sale can be found here. Corporate insiders own 40.50% of the company’s stock.
A number of institutional investors have recently bought and sold shares of TSRO. CenturyLink Investment Management Co purchased a new position in Tesaro during the third quarter worth about $172,000. KCG Holdings Inc. purchased a new position in Tesaro during the second quarter worth about $228,000. Quantitative Systematic Strategies LLC purchased a new position in Tesaro during the second quarter worth about $240,000. Bluestein R H & Co. purchased a new position in Tesaro during the second quarter worth about $252,000. Finally, Neuberger Berman Group LLC purchased a new position in Tesaro during the second quarter worth about $256,000. Institutional investors and hedge funds own 88.81% of the company’s stock.
Tesaro Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.
Receive News & Ratings for Tesaro Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tesaro Inc. and related companies with MarketBeat.com's FREE daily email newsletter.